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Abstract A 35-year-old woman with a 9-year history of
Grave’s disease delivered a male infant weighing 2,210 g
at 32 weeks of gestation by caesarean section. The neonate
developed thyrotoxicosis and, at the age of 24 h, was
treated with oral carbimazole (500 lg every 8 h) and
propranolol (2 mg/kg/day in two divided doses). He sub-
sequently developed hypertension on day 4, which re-
quired therapy with amlodipine (0.1 mg once daily).
Severe hypotension developed within 24 h and required
discontinuation of amlodipine, with initiation of intra-
venous inotropic support with dopamine and dobutamine
(at a rate of 20 lg/kg/min). The blood pressure rapidly
normalized, and both dopamine and dobutamine infusions
were stopped within 36 h. A Naranjo assessment score of 6
was calculated, indicating that the severe hypotension was
a probable adverse drug reaction caused by the combina-
tion of amlodipine and propranolol therapy.
Key Points
Antihypertensive medication combination therapy in
neonates should be monitored closely for
hypotension.
The interaction of a beta blocker and amlodipine
therapy in the neonatal period needs to be studied
further.
Introduction
Neonatal hypertension secondary to renal, endocrine or
other causes is commonly seen in sick newborn infants [1].
Its treatment may include use of beta blockers, vasodilators
such as hydralazine, calcium channel blockers or alpha
blockers. Although amlodipine has been shown to be ef-
fective and safe when used in children [2], its use has not
been fully studied in neonates nor in combination with beta
blockers in that age group. However, amlodipine was listed
in a recent review article as one of the treatment options for
hypertension in neonates [3].
In an infant born to a mother with Grave’s disease, we
report the occurrence of severe hypotension, which de-
veloped after amlodipine was administered in addition to
the beta blocker therapy already initiated for hypertension
secondary to thyrotoxicosis. We describe the case and
discuss the use of amlodipine in this age group.
Case Report
A male newborn infant, with a birth weight of 2,210 g, was
born by caesarean section at 32 weeks of gestation to a
35-year-old mother with a 9-year history of Grave’s dis-
ease. He required mechanical ventilation for 3 days for
respiratory distress syndrome. Thyrotoxicosis was con-
firmed by physical examination and laboratory investiga-
tions: his serum thyroxin (T4) level was 59 ng/dL and his
thyroid stimulating hormone (TSH) level was 0.013 lIU/
mL. Oral treatment with carbimazole 500 lg every 8 h and
propranolol 2 mg/kg/day, divided into two doses, was
started at 24 h after birth. On day 4, the infant developed
hypertension, with a mean blood pressure ranging from 90
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to 100 mmHg. On the recommendation of a paediatric
nephrologist, therapy with amlodipine 0.1 mg orally once
daily was started.
Twenty hours after administration of the first dose of
amlodipine, the child developed severe hypotension, with a
mean blood pressure of 27 mmHg, and required supportive
care with mechanical ventilation and intravenous inotropes
(dopamine and dobutamine at a rate of 20 lg/kg/min).
Amlodipine was stopped, propranolol therapy was contin-
ued, a full septic work-up was performed and all cultures
showed no bacterial growth. Following the discontinuation
of amlodipine, the blood pressure normalized, and the
inotropes were stopped within 36 h. By day 8, propranolol
was discontinued, as the blood pressure and serum T4 level
(14.7 lg/dL) were normal.
Discussion
This case report aims to describe the occurrence of severe
hypotension following amlodipine administration for hy-
pertension developing in a preterm infant with thyro-
toxicosis who was already receiving beta blocker. This is
similar to the findings in an animal study by Ishizaka et al.
[4], where more significant hypotension occurred when a
beta blocker was added to amlodipine than when it was
added to a newer calcium channel blocker.
Recent research supports the use of amlodipine, a cal-
cium channel blocker, in young children. Robinson et al.
[5] described its use in 33 children aged 1.3–16.9 years and
showed that it was well tolerated when used for 6 months.
Lago Rivero et al. [6] reported its use in refractory hy-
pertension in a 5-year-old girl with secondary hyperten-
sion. By contrast, there have been no good studies on the
use of calcium channel blockers in neonates. One case
report described the development of subcutaneous fat
necrosis in a newborn whose mother had received a cal-
cium channel blocker [7]. A case report of death caused by
an amlodipine overdose recommended caution when using
it in young infants [8].
The current report suggests that severe hypotension may
result from combining amlodipine with beta blocker ther-
apy in neonates. Combination antihypertensive therapy in
this age group should be used only with caution.
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